Boston Sci invests $37M in Irish facility

Boston Scientific ($BSX) is investing €26 million ($37 million) in R&D at its Clonmel facility in Ireland. The investment will allow the company to expand its R&D and technical capabilities related to the design of its next-generation cardiac rhythm management devices manufactured at that facility. The investment is supported by the government through IDA Ireland.

"This local funding will benefit our Cardiology, Rhythm and Vascular Group by enhancing our ability to provide R&D, design and manufacturing support for our leading medical device technologies," Brad Sorenson, VP of operations for Boston Scientific, says in an IDA Ireland statement. "I am confident that, with the talent and expertise of our Clonmel staff, we can continue to successfully commercialize new life-saving innovations for our customers and their patients worldwide."

Boston Scientific established operations in Ireland in 1994 and is one of the country's largest employers, with campuses in Clonmel, Galway and Cork.

- see the IDA Ireland statement

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.